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Interferons (IFNs) are a family of cytokines with growth inhibitory, and antiviral functions. IFNs exert their biological actions through the
expression of more than 1000 IFN stimulated genes, ISGs. ISG12 is an IFN type I induced gene encoding a protein of Mr 12,000. We have
identified a novel, IFN inducible splice variant of ISG12 lacking exon 2 leading to a putative truncated protein isoform of Mr 7400, ISG12-S.
In cells from blood and cervical cytobrush material from healthy women, the level of ISG12-S expression was higher than ISG12 expression,
whereas the expression pattern was more evenly distributed between ISG12 and ISG12-S in breast carcinoma cells, in cancer cell lines and in
cervical cytobrush material with neoplastic lesions. In addition, we have found a nine-nucleotide deletion situated in exon 4 of the ISG12
gene. This deletion leads to a three-amino-acid deletion (AMA) in the putative ISG12 gene products, ISG12D and ISG12-SD. We have
determined the prevalence of the deletion ISG12D in normal and neoplastic cells. Homozygosity ISG12(0/0) and ISG12(D/D), and
heterozygosity ISG12(0/D) were found, although the ISG12(D/D) genotype was rare. In heterozygous cells from cytobrush material with
neoplastic lesions, we found a preference for expression of the ISG12(0) allele.D 2003 Elsevier Science B.V. All rights reserved.Keywords: ISG12; ISG12-S; IFNa; IFNh; Cervix cancer; Breast cancer
1. Introduction Leu-13, and 1-8U still remains relatively uncharacterisedInterferons (IFNs) are a family of cytokines in vertebrates
with a variety of biological functions, such as growth
inhibition, antitumoural, immunomodulatory, antiviral, and
anti-parasitic actions. Human IFNs are grouped into type I
and type II, and the biological actions of IFNs are mainly
mediated through the gene products of more than 1000 IFN
stimulated genes (ISGs), updated in http://www.lerner.ccf.
org/labs/williams, and reviewed in Refs. [1,2]. The ISGs
best characterised are PKR, the 2V–5VOligoadenylate Syn-
thetases, RNase L and Mx-GTPases (reviewed in Refs. [3–
6]). A group of small ISGs consisting of ISG12, 6-16, 9-27/0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00087-5
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South Mimms, Hertfordshire EN6 3LD, UK.and their functions are still basically unknown [7–10].
The cDNA of ISG12 (ISG protein of Mr 12,000) was
originally cloned as an oestrogen induced gene in the
human breast epithelial cell line MCF7, and designated
p27 [10]. We have previously demonstrated by quantitative
reverse transcription (RT)-PCR that ISG12 is highly induc-
ible by IFNa in human cell lines of different origins [11].
The ISG12 gene encodes a hydrophobic protein of 122
amino acids, which is localised to the nuclear membrane
[12]. The existence of two splice variants in the 5V untrans-
lated region (UTR) of the ISG12 gene leading to the same
ISG12 open reading frame (ORF) has previously been
shown [12].
This report describes a novel splice variant of the ISG12
gene lacking exon 2, leading to a putative truncated isoform
of Mr 7400, ISG12-S. Furthermore, analyses of genomic
ISG12 sequences revealed a nine-nucleotide deletion within
the ISG12 ORF, leading to a putative ISG12D protein with aed.
Table 1
Primers
Sequence Position
ISG12( 94f) 5V AGA CGG TGA GGT CAG CTT C 3V Exon 1
ISG12( 19f) 5V GGA ATT AAC CCG AGC AGG C 3V Exon 2
ISG12( + 7f) 5V GCC TCT GCT CTCACC TCA T 3V Exon 2
ISG12( + 92f) 5V CCA GGA TTG CTA CAG TTG T 3V Exon 3
ISG12( + 103r) 5V CTC CTC CAA TCA CAA CTG T 3V Exon 3
ISG12( + 318r) 5V GGA GCC CAG GAT GAA CTT G 3V Exon 5
ISG12( + 3931f) 5V CTG GCT GTG CTC CCC TTG A 3V Exon 4
ISG12( + 3934f) 5V GCT GTG CTC CCC TTG ATT CG 3V Intron 3
ISG12( + 4172r) 5V ATA GCA GCC AAG ATG ATG T 3V Exon 4
ISG12( + 4261r) 5V GCC CCG CCA GGA TAC TTA C 3V Intron 4
GAPDH( + 75f) 5V GGT CGG AGT CAA CGG ATT T 3V
GAPDH( + 314r) 5V CCA GCA TCG CCC CAC TTG A 3V
Fig. 1. RT-PCR analyses of isg12 mRNA. mRNA was isolated from blood
samples (lanes 1–2), a normal cytobrush sample (lane 3), cytobrush
samples with neoplastic lesions (lanes 4–5), HeLa cells (lane 6), MCF10A
cells (lane 7), and breast tumours (lanes 8–12). RT-PCRs were performed
using ISG12 primers positioned in exons 1 and 5 followed by a semi-nested
PCR with primers positioned in exons 1 and 3. A negative control without
template cDNAwas included (lane 13). PCR products were applied to a 1%
agarose gel and visualised by ethidium bromide staining. The amplified
ISG12 products are marked with arrows: S: isg12-S, a: isg12a, b: isg12b,
and c: isg12c.
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ISG12 deletion (D) in the genome and the level of tran-
scription of each allele have been examined in various cell
types.2. Materials and methods
2.1. Cell lines
The human cervical cancer cel l l ines C-33A
(ATCC#HTB-31), SiHa (ATCC#-HTB-35), and Hela
(ATCC#CCL2), the fibrosarcoma cell line HT1080
(ATCC#CCL121), and the amniotic epithelial cell line
AMA [13] were grown as monolayers in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Gibco BRL/Life Technol-
ogies). The human cervical cancer cell line Ca Ski
(ATTC#CRL-1550) and the keratinocyte cell line SVK14
[14] were grown as monolayers in RPMI medium (Gibco
BRL/Life Technologies). SK-OV3 (ATCC#HTB-77), an
ovarian cancer cell line, was grown as monolayer in
McCoy’s 5a medium (Life Technologies). All media were
supplemented with 10% newborn calf serum (Gibco BRL/
Life Technologies) and antibiotics [100 international units
(IU)/ml Penicillin and 50 Ag/ml Streptomycin]. The breast
cancer cell line MCF10A (ATCC#CRl-10317) was grown in
DMEM/F12 medium without phenol red (Gibco BRL/Life
Technologies) supplemented with 0.5 Ag/ml Hydrocortisone
(Sigma), 100 ng/ml Choleratoxin (Calbiochem), 20 ng/ml
epidermal growth factor (EGF) (Sigma), 10 Ag/ml insulin
(Sigma), and 5% horse serum (Life Technologies). Cells at
80% confluence were harvested by scraping with a rubber
policeman. Treatment with 500 U/ml IFNa or IFNh was
carried out for 24 h.Fig. 2. Alternative splicing of the ISG12 gene. (A) Multiple alignment of ISG12
HSA294851, isg12bD: THC662717, isg12cD: AY126456, ISG12-S: AY126457
sequence). Putative ATG start codons are underlined. + 1 indicates the first nucle
variants with a nine-nucleotide deletion in exon 4. Capital letters are exon and sma
the alternative splicing events (not drawn to scale). * putative start codons. An a2.2. 5VRACE
The 5V end ISG12 cDNA clones were obtained from
HeLa and AMA cells, as described [12]. The longest clones
were analysed previously, but due to the appearance of the
small bands after RT-PCR, the shorter clones were se-
quenced. Furthermore, the sequences of the long clones
were analysed further downstream. These sequences have
been deposited in the EMBL database (for nomenclature,
see Table 2): isg12b, accession number HSA294851;
isg12cD, accession number AY126456; isg12-S, accession
number AY126457, and isg12-SD, accession number
AY126458.
2.3. Alignment
The alignments were performed with cDNA sequences
from the 5V RACE clones isg12b, isg12cD, isg12-S, and
isg12-SD, and with sequences from the Tentative Human
Cluster collection (http://www.tigr.org): THC662717
corresponding to isg12bD and THC662718 corresponding
to isg12a [10], together with the genomic ISG12 sequence
(AL079302). The ClustalW program was used (www.ch.
embnet.org).
2.4. Blood samples
From eight healthy volunteers, a 2-ml heparin-blood
sample was collected. The leucocyte mRNA Isolation kit
(DYNALR) was used for isolation of the leucocytes fol-
lowed by isolation of mRNA. The DNA DIRECTk System
I (DYNALR) was used for isolation of genomic DNA from
the heparin-blood.cDNA sequences and genomic ISG12 DNA. isg12a: THC662718, isg12b:
, and ISG12-SD: AY126458, Chr 14: AL079302 (The genomic ISG12
otide in the ISG12 sequences (genomic DNA and cDNA). D indicates the
ll letters intron sequences. (B) Intron–exon structure of the ISG12 gene and
rrowhead marks the position of the (D) deletion.
AB
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Table 2
Nomenclature
ISG12 gene
ISG12(0/0) 0/0
ISG12(0/D) 0/[g.4103_4111del]
ISG12(D/D) [g.4103_4111del]/[g.4103_4111del]
ISG12 cDNAs
isg12a isg12
isg12b isg12[c.-58_-25del]
isg12c isg12[c.-94_-25del]
isg12-S isg12[c.-58_91del]
isg12a(D) isg12[c.126_134del]
isg12b(D) isg12[c.-58_-25del; c.126_134del]
isg12c(D) isg12[c.-94_-25del; c.126_134del]
isg12-S(D) isg12[c.-58_91del; c.126_134del]
Putative ISG12 isoforms
ISG12 p.ISG12
ISG12D p.ISG12(A43_A45del)
ISG12-S p.ISG12(M1_A43del)
ISG12-SD p.ISG12(M1_P48del)
GAPDH
a
b
S
Fig. 3. IFN induction of isg12-S. mRNA was isolated from SK-OV3 cells
treated with IFNa (a), IFNh (h), or left untreated (0) as indicated. RT-PCR
was carried out using ISG12 specific primers situated in exons 1 and 5.
GAPDH amplification was used as control. The positions of PCR products
from the ISG12 splice variants isg12a (a), isg12b (b), and isg12-S (S), as
well as GAPDH are marked with arrows.
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The protocol followed the Helsinki declaration guide-
lines and was approved by Aarhus County Ethics Commit-
tee. All women gave their written informed consent before
they were enrolled in the project. Samples were collected
from seven women with known neoplastic lesions [Cervical
Intraepithelial Neoplasia (CIN) 1–3] and seven healthy
women. Cells were washed thoroughly from the cytobrush
with 200 Al cold PBS (140 mM NaCl2, 6.5 mM Na2HPO4,
1.5 mM KH2PO4; pH 7.2), centrifuged and washed three
times in cold PBS. The cells were resuspended in PBS,
divided in two, and used for isolation of mRNA and DNA,
respectively.
2.6. Breast tumour samples
Total RNA and cDNAwas produced as described in Ref.
[15], and used for ISG12 specific PCR analysis with
GAPDH RT-PCR as control.
2.7. Isolation of mRNA and DNA from cell cultures and
cervical cytobrush material
Genomic DNA and mRNA were isolated from cell
pellets with DNA DIRECTk or mRNA DIRECTk System
I (from DYNALR), respectively.
2.8. RT-PCR
0.3–25 ng mRNA was used for synthesising first-strand
cDNA in a total volume of 50 Al in 50 mM Tris–Cl (pH
8.3), 10 mM MgCl2, 75 mM KCl, 0.01 M DTT, 0.25 mM
dNTP, 1 U MMLV Reverse Transcriptase (Epicentre), and
0.8 pmol/Al oligo(dT)18 primer. The PCR was performed ina total volume of 30 Al in 10 mM Tris–Cl (pH 8.3), 50 mM
KCl, 0.125 mM MgCl2 with 1.5 Al cDNA template, 4%
DMSO, 1 M Betain, 0.2 mM dNTP, 1 U Taq Goldk
polymerase (Perkin Elmer), 1 pmol/Al reverse and forward
primers. The sequence of the primers used is listed in Table
1. ISG12 splice variants were investigated using the primers
ISG12( 94f) and ISG12( + 318r) or ISG12( + 103r). The
ISG12( + 318r) and ISG12( + 103r) primers were labelled
with the fluorescent dye 5-FAM when used for capillary
electrophoresis. The PCR was performed with the following
parameters: 95 jC for 15 min for the first cycle followed by
40 cycles at 94 jC for 30 s; 55 jC for 30 s;72 jC for 30 s,
and finally 72 jC for 10 min. When analysing IFN induc-
tion, 30 cycles were used. The following ISG12 specific
primers were used for analysis of the ISG12 (D) deletion:
ISG12( 19f) or ISG12( + 92f) and ISG12( + 318r) with
annealing temperature 53 jC. The GAPDH specific primers
GAPDH(75f) and GAPDH(314r) were used as an internal
control with annealing temperature 50 jC.
2.9. PCR of genomic DNA
Isolated genomic DNA from blood samples, cell cultures
and cervical cytobrush material was amplified using the
same PCR conditions as for RT-PCR. The following primers
were used: ISG12( + 3931f) and ISG12( + 4261r) with
annealing temperature 54 jC. ISG12( + 4261r) was labelled
with the fluorescent dye 5-FAM in the 5Vend.
2.10. Gel electrophoresis
The PCR fragments labelled with 5-FAM were subjected
to capillary electrophoresis (ABI 310 Applied Biosystems)
and analysed by the software GeneScank and Gen-
oTyperk (Applied Biosystems). Eight-microliter aliquots
Fig. 4. Identification of the ISG12 splice variants. mRNAwas isolated from
endocervical samples, (A) with a neoplastic lesion, and (B) from a healthy
control. (C) A blood sample. RT-PCR was performed with primers
positioned in exons 1 and 3. The PCR products were analysed by capillary
electrophoresis, and fragment sizes established with the GeneScank
software. Peaks marked with arrows indicate the position of RT-PCR
products from a: isg12a; b: isg12b, c: isg12c, and S: isg12-S transcripts. The
numbers are integrated areas of the peaks (in abitrary units).
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gels and visualised by ethidium bromide staining.
2.11. Sequencing
0.2–2.0 Ag amplified DNA was subjected to sequencing
on an ABI 373 automated sequencer using the nested
primers ISG12( + 7), ISG12( + 3934f), or ISG12( + 4172r)Fig. 5. Identification of the ISG12 (D) deletion genotype. Genomic DNA
was isolated from cells, and PCR analyses were carried out with primers
flanking the (D) deletion. PCR products were analysed by capillary
electrophoresis, and fragment sizes established with the GeneScank
software. Genomic DNA from a heterozygous ISG12(0/D) (upper panel) or
a homozygous ISG12(0/0) (lower panel) blood sample. PCR products from
ISG12(0) and ISG12(D) alleles are indicated by arrows. L: length of PCR
product in base pairs. H: integrated area of the peak (in abitrary units).and the Thermo Sequenase II dye Terminator cycle sequenc-
ing kit (Amersham Pharmacia Biotech).3. Results
When studying the splice variations (isg12a and isg12b)
previously found in the 5VUTR of ISG12 mRNA [12], we
observed two additional smaller products after RT-PCR (Fig.
1). Sequencing the smallest PCR product and comparing this
sequence to the intron–exon structure of the ISG12 genomic
sequence, we could deduce that it was derived from an
alternatively spliced ISG12 mRNA lacking exon 2, isg12-
S. The other transcript lacks exons 1b and 2a, and was
designated isg12c. Isg12a and isg12b transcripts were previ-
ously identified by sequencing 5VRACE clones. By sequenc-
ing 5VRACE clones with small inserts, both isg12-S and
isg12c splice variants were found in HeLa and AMA cells,
and the sequences are shown in Fig. 2A. Isg12-S encodes a
putative truncated isoform ISG12-S with Mr 7400, whereas
isg12c encodes full length ISG12. The nucleotide sequenceFig. 6. Transcription of ISG12 alleles with or without the (D) deletion.
mRNA was isolated from cells, and RT-PCR was performed with primers
positioned in exons 3 and 5. All samples are heterozygous ISG12(0/D). (A)
Normal endocervical sample, (B) blood sample, and (C) the SVK14 cell
line. PCR products from isg12 (0) and isg12D (D) cDNAs are indicated by
arrows. L: length of PCR product in base pairs. H: integrated area of the
peak (in abitrary units).
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Kozak sequence for translational start sites [16].
When comparing the amount of PCR product from
isg12-S to that of isg12a, isg12b, and isg12c, it can be
seen that the expression pattern varies, as exemplified in
Fig. 1. In normal tissue from blood and cervix, isg12-S is
preferentially expressed, whereas in breast carcinomas, in
endocervical cells with neoplastic lesions, and in the carci-
noma cell lines, the isg12 mRNAs encoding full-length
ISG12 become more abundant. These results were confirmed
for all samples using capillary electrophoresis as shown in
Fig. 4.
Alignment of the two ISG12 THCs (Tentative Human
Clusters from www.tigr.org) revealed that one of the groups
possessed a nine-nucleotide deletion in the coding region of
ISG12. Furthermore, aligning ISG12 cDNA sequences with
the two ISG12 genomic sequences published (AL121838
and AL079302) demonstrated that this deletion could not be
the result of an alternative splicing event, since it wasFig. 7. Prevalence of the ISG12 (D) deletion. The samples were classified
ISG12(0/D) = ISG12(0/D), as described in Fig. 5. The transcription of the ISG12(0)
both ISG12 alleles in equal amount is indicated by cDNA (0/D). gDNA indicates
SVK14, SK-OV3, and MCF10A. (B) Blood samples from healthy volunteers. (C)
women with intraepithelial neoplastic lesions (CIN 1–3). D =D.positioned in exon 4 (Fig. 2A and B). Noteworthy, both
genomic sequences of ISG12 harboured this nine-nucleotide
deletion. The nine-nucleotide deletion in isg12 mRNA gives
rise to a three-amino-acid deletion (AMA) in the putative
gene product, ISG12D. If the isg12D transcript is subjected
to the alternative splicing leading to excision of exon 2, the
putative start codon of isg12-S is deleted. Therefore, the
isg12-SD transcript encodes a putative protein ISG12-SD
truncated by five amino acid residues in the N terminus
compared to ISG12-S. The putative start codon of isg12-SD
situated in exon 4 is also consistent with the Kozak
sequence for translational start.
Alignment of the alternatively spliced ISG12 mRNA
sequences identified thus far, with the ISG12 gene on
chromosome 14 is shown in Fig. 2A. The alternative splicing
events are depicted in Fig. 2B. All splice sites are in
accordance with consensus splicing sequences. The ISG12
nomenclature [17] and the abbreviations for the ISG12
variants used in this paper are listed in Table 2.as homozygous ISG12(0/0), ISG12(D/D) = ISG12(D/D), or heterozygous
or the ISG12(D) allele was monitored, as described in Fig. 6. Transcription of
genomic DNA. (A) The cell lines: C-33A, SiHa, Ca Ski, HeLa, HT1080,
Endocervical samples from healthy controls. (D) Endocervical samples from
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variant isg12-S was inducible by type 1 IFN. For this
purpose, we employed RT-PCR using ISG12 specific
primers situated in exons 1 and 5, and GAPDH amplifi-
cation as control. The result from the ovarian cell line SK-
OV3 showed that isg12-S was indeed inducible by IFNa
and IFNh (Fig. 3). Similar results were obtained for the
other cell lines.
To study the relative expression levels of the ISG12
splice variants, we used capillary electrophoresis and Gene
Scan of RT-PCR products to analyse the expression pattern
of ISG12 cDNA. The ISG12 splice variants present in a
blood sample and in two endocervical samples, one with
neoplastic lesion, and one from a healthy control, are shown
in Fig. 4. From these studies, we could conclude that all of
the cells expressed the isg12-S transcript. The transcripts
isg12a and isg12b were present in most of the cells, whereas
the isg12c transcript was present in some of the cells. The
isg12-S transcript was preferentially expressed in normal
cells, whereas in the carcinoma cell lines, in cells from
breast carcinomas, and in endocervical cells with neoplastic
lesions, the expression of full-length isg12 and isg12-S
transcripts was more evenly distributed (Figs. 1 and 4).
To identify the prevalence of the ISG12 (D) deletion in
the study material, we analysed all samples by capillary
electrophoresis. Some of the samples were also sequenced
using primers flanking exon 4 of the ISG12 genomic DNA.
We were thus able to identify homozygosity ISG12(0/0) and
ISG12(D/D) and heterozygosity ISG12(0/D) in the cells. A
homozygous ISG12(0/0) and a heterozygous ISG12(0/D)
blood sample are shown in Fig. 5.
Similarly, we were able to analyse how the two alleles
were transcribed using RT-PCR and capillary electrophore-
sis. By comparing the mutual intensity of the two peaks
from heterozygous cells by Gene Scan analysis, we were
able to compare the level of expression of each allele as
shown in Fig. 6.
All the samples were tested for the prevalence of the
ISG12 (D) deletion in the gene and the cDNAs expressed,
and the results for the four groups of samples are added up
in Fig. 7. For the cell lines, five of eight were homozygous
ISG12(0/0), and the cell lines SK-OV3, SVK14 and HeLa
were heterozygous ISG12(0/D) (Fig. 7A). HeLa expressed
the ISG12(0) allele while SK-OV3 showed expression
preference for the ISG12(D) allele. SVK14 showed no
preference, that is, both ISG12 alleles were expressed in
equal amounts. Of the eight blood samples from healthy
donors, six were homozygous ISG12(0/0), whereas one was
heterozygous ISG12(0/D), and one was homozygous
ISG12(D/D) (Fig. 7B).
The results from cervical cytobrush material from normal
tissue and tissue with neoplastic lesions, respectively, are
shown in Fig. 7C and D. From normal endocervical tissue,
five of seven samples were homozygous ISG12(0/0), and
two were heterozygous ISG12(0/D). One of the two hetero-
zygous samples expressed preferentially the ISG12(0) allele,while the other expressed both alleles at equal amounts. In
the cytobrush samples with neoplastic lesions, six of seven
cervical cytobrush samples were heterozygous for the
ISG12 (D) deletion, and one was homozygous ISG12(0/0).
Six of six heterozygous cytobrush samples with neoplastic
lesions preferentially expressed the ISG12(0) allele. None of
the tested cervical cytobrush samples were homozygous
ISG12(D/D).4. Discussion
We have shown the existence of several alternative splice
variants of the human ISG12 gene. Three of these splice
variations are positioned in the 5V UTR and encode a full-
length ISG12 protein. One splice variant isg12-S leads to a
deletion of exon 2 harbouring the start codon, and conse-
quently encodes a putative protein of Mr 7400, ISG12-S.
Furthermore, we have described a deletion of nine
nucleotides in exon 4 of the ISG12 gene. These nine
nucleotides are in frame and encode the three amino acids
AMA. Thus, two isoforms of full length exist, ISG12 and
ISG12D. In addition, the truncated isoform also exists in
two variants, ISG12-S and ISG12-SD. ISG12-SD lacks five
amino acid residues at the N terminus compared to ISG12-S.
In total, four putative ISG12 isoforms have been identified.
We have analysed the prevalence of the four ISG12 iso-
forms in normal tissue (blood and cervical cytobrush material
from healthy women), in cell lines and in cervical cytobrush
material from women with intraepithelial cervical lesions.
From these experiments, we can conclude that the ISG12(D/
D) genotype is very rare, and that the transcription of the
ISG12(0) allele is preferred in heterozygous endocervical
cells with neoplastic lesions. Furthermore, in normal tissue
from blood and cervix, the ISG12-S variants are preferen-
tially expressed, whereas in breast carcinomas, in endocer-
vical cells with neoplastic lesions, and in the carcinoma cell
lines, the full-length ISG12 variants become more abundant.
We have previously shown that ISG12 full length is
localised to the nuclear membrane [12]. Further studies are
needed to determine whether this localisation also applies
for the other ISG12 isoforms: ISG12D, ISG12-S, and
ISG12-SD.
In breast tissue sections analysed for expression of ISG12
mRNA by in situ hybridisation, it has previously been
shown that a high level of expression was found in cancer
cells in most of the sections, while no ISG12 transcripts
could be detected in normal cells of the sections [10]. From
these experiments, it is not possible to determine, which of
the ISG12 isoforms is up-regulated. It could be hypothes-
ised that the expression pattern of ISG12 isoforms in cancer
tissue is changed compared to normal tissue. We have
observed in breast carcinomas that both full-length isg12
and isg12-S were expressed.
It has also been shown that the overall ISG12 expression
levels vary in human endometrium during the menstrual
K.C.J. Smidt et al. / Biochimica et Biophysica Acta 1638 (2003) 227–234234cycle [18]. However, the expression pattern of ISG12 iso-
forms was not analysed, and could play a role for the
function.
Type 1 IFN has an overall antiviral effect, which is
carried out by individual IFN induced proteins. It has been
shown by micro-array studies that IFN induced genes are
up-regulated 24 h after Human Cytomegalovirus infection
of human foreskin keratinocytes [19]. In these studies,
ISG12 was up-regulated 7-fold 24 h post infection. How-
ever, some viruses interfere with the IFN system by inhibit-
ing components of the signal transduction pathway or
specific IFN induced proteins. Human Papillomavirus
(HPV) infection of keratinocytes leads to down-regulation
of the IFN system [20,21], and ISG12 was one of the most
down-regulated genes. Profile analysis of ISG12 isoform
expression in these array studies could shed light on
possible diverse functions of the isoforms.
The aetiology of cervical cancer is persistent HPV infec-
tion. The majority of females have been infected by HPV, but
only a small proportion fails to clear the virus. These women
develop persistent intraepithelial cervical neoplasia and in
few cases invasive cervical cancer. The lack of virus clear-
ance in some women points to an intraindividual response to
HPV infection, which theoretically could be mediated by
IFN stimulated genes like ISG12.Acknowledgements
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